Q-omics provides the consensus-scored RN7SKP182 profile across patient tissues and cancer cell-line models. RN7SKP182 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RN7SKP182 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, RN7SKP182 RNA expression shows 8,993 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight THCA, LUSC, and COAD as cancer lineages where RN7SKP182 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SKP182 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SKP182 survival associations across molecular data types. RN7SKP182 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SKP182 RNA expression–survival associations across cancer types. High RN7SKP182 expression shows unfavorable associations in THCA, KIRC, ESCA, KIRP and LGG, but favorable associations in LUAD. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify THCA as the clearest survival context for RN7SKP182 RNA expression.
This table summarizes RN7SKP182 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SKP182. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SKP182 shows higher tumor expression in LUSC. The LUSC box plot shows higher RN7SKP182 RNA expression in tumor versus normal tissue (log2 FC = +0.053, t-test p = .014).
This table shows molecular features associated with RN7SKP182 in patient tissues and cancer cell lines. In patient samples, RN7SKP182 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
